Norvium Bioscience Company Profile
✉ Email this page to a colleague
What is the competitive landscape for NORVIUM BIOSCIENCE, and what generic alternatives to NORVIUM BIOSCIENCE drugs are available?
NORVIUM BIOSCIENCE has two hundred and forty-seven approved drugs.
There are four US patents protecting NORVIUM BIOSCIENCE drugs. There is one tentative approval on NORVIUM BIOSCIENCE drugs.
There are fifty-one patent family members on NORVIUM BIOSCIENCE drugs in twenty-one countries and five hundred and forty-one supplementary protection certificates in seventeen countries.
Summary for Norvium Bioscience
| International Patents: | 51 |
| US Patents: | 4 |
| Tradenames: | 197 |
| Ingredients: | 185 |
| NDAs: | 247 |
Drugs and US Patents for Norvium Bioscience
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Norvium Bioscience | GABAPENTIN | gabapentin | TABLET;ORAL | 090335-001 | Jun 1, 2010 | DISCN | No | No | ⤷ Subscribe | ⤷ Subscribe | |||||
| Norvium Bioscience | RANITIDINE HYDROCHLORIDE | ranitidine hydrochloride | CAPSULE;ORAL | 075564-002 | Oct 27, 2000 | DISCN | No | No | ⤷ Subscribe | ⤷ Subscribe | |||||
| Norvium Bioscience | NAPROXEN SODIUM | naproxen sodium | TABLET;ORAL | 074367-002 | Aug 31, 1994 | DISCN | No | No | ⤷ Subscribe | ⤷ Subscribe | |||||
| Norvium Bioscience | TERAZOSIN HYDROCHLORIDE | terazosin hydrochloride | CAPSULE;ORAL | 075140-002 | Feb 11, 2000 | DISCN | No | No | ⤷ Subscribe | ⤷ Subscribe | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Norvium Bioscience
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Norvium Bioscience | DEMADEX | torsemide | TABLET;ORAL | 020136-002 | Aug 23, 1993 | RE30633 | ⤷ Subscribe |
| Norvium Bioscience | MIACALCIN | calcitonin salmon | SPRAY, METERED;NASAL | 020313-002 | Aug 17, 1995 | 5,759,565 | ⤷ Subscribe |
| Norvium Bioscience | LUXIQ | betamethasone valerate | AEROSOL, FOAM;TOPICAL | 020934-001 | Feb 28, 1999 | 6,126,920 | ⤷ Subscribe |
| Norvium Bioscience | DEMADEX | torsemide | TABLET;ORAL | 020136-003 | Aug 23, 1993 | 4,822,807 | ⤷ Subscribe |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for NORVIUM BIOSCIENCE drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Foam | 2% | ➤ Subscribe | 2009-07-30 |
| ➤ Subscribe | Topical Foam | 0.05% | ➤ Subscribe | 2005-06-27 |
| ➤ Subscribe | Ophthalmic Solution | 0.05% | ➤ Subscribe | 2006-12-13 |
| ➤ Subscribe | Nasal Spray | 0.125 mg base/spray | ➤ Subscribe | 2005-11-14 |
| ➤ Subscribe | Foam | 0.12% | ➤ Subscribe | 2007-08-10 |
| ➤ Subscribe | Delayed-release Tablets | 20 mg | ➤ Subscribe | 2015-06-03 |
| ➤ Subscribe | Inhalation Solution | 0.021% and 0.042% | ➤ Subscribe | 2005-10-19 |
International Patents for Norvium Bioscience Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Brazil | PI0514806 | ⤷ Subscribe |
| Poland | 1796636 | ⤷ Subscribe |
| Eurasian Patent Organization | 014372 | ⤷ Subscribe |
| European Patent Office | 2438910 | ⤷ Subscribe |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Norvium Bioscience Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1663240 | 59/2015 | Austria | ⤷ Subscribe | PRODUCT NAME: KOMBINATION VON RILPIVIRIN ODER EINEM PHARMAZEUTISCH ANNEHMBAREN SALZ VON RILPIVIRIN, EINSCHLIESSLICH DES HYDROCHLORIDSALZES VON RILPIVIRIN, TENOFOVIR, INSBESONDERE TENOFOVIRDISOPROXILFUMARAT, UND EMTRICITABIN; REGISTRATION NO/DATE: EU/1/11/737/001-002 20111128 |
| 2822954 | SPC/GB18/031 | United Kingdom | ⤷ Subscribe | PRODUCT NAME: BICTEGRAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR BICTEGRAVIR SODIUM.; REGISTERED: UK EU/1/18/1289/001(NI) 20180625; UK EU/1/18/1289/002(NI) 20180625; UK PLGB 11972/0008 20180625 |
| 0914118 | PA2007001 | Lithuania | ⤷ Subscribe | PRODUCT NAME: DEFERASIROXUM; REGISTRATION NO/DATE: EU/1/06/356/001 2006 08 28, EU/1/06/356/002 2006 08 28, EU/1/06/356/003 2006 08 28, EU/1/06/356/004 2006 08 28, EU/1/06/356/005 2006 08 28, EU/1/06/356/00 20060828 |
| 1506211 | C 2014 029 | Romania | ⤷ Subscribe | PRODUCT NAME: COMBINATIE DE DAPAGLIFLOZIN SAU O SARE ACCEPTABILAFARMACEUTIC A ACESTUIA SI METFORMINA SAU O SARE ACCEPTABILA FARMACEUTIC A ACESTEIA; NATIONAL AUTHORISATION NUMBER: EU/1/13/900; DATE OF NATIONAL AUTHORISATION: 20140116; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/13/900; DATE OF FIRST AUTHORISATION IN EEA: 20140116 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
